01 / DESIGN
What was studied?
Adults already receiving basal insulin were randomized to cagrilintide-semaglutide or placebo in a forty-week blinded study.
02 / FINDINGS
What did the researchers report?
The combination reduced glycated hemoglobin and body weight relative to placebo added to background treatment. The report also assessed hypoglycemia and adverse events.
03 / LIMITS
How should it be interpreted?
This answers an add-on question in insulin-treated diabetes. It is not evidence for replacing background treatment or for using catalog materials as pharmaceutical substitutes.
Loti Labs Peptide editorial reading note. Based on the linked source record. Methods and corrections.